Valuation: CEL-SCI Corporation

Market Cap 2.55Cr 2.29Cr 2.09Cr 1.91Cr 3.6Cr 239.74Cr 3.71Cr 25Cr 10Cr 127.92Cr 9.57Cr 9.37Cr 403.84Cr P/E 2026 *
-0.47x
P/E 2027 * -0.23x
Enterprise Value 2Cr 1.79Cr 1.64Cr 1.49Cr 2.81Cr 187.53Cr 2.9Cr 20Cr 7.86Cr 100.06Cr 7.49Cr 7.33Cr 315.89Cr EV / Sales 2026 *
-
EV / Sales 2027 * 3.38x
Free-Float
96.29%
Yield 2026 *
-
Yield 2027 * -
26/10 CEL-SCI Corporation Presents New Phase 3 Multikine Data and Positive New Pre-Surgical Tumor Response and Safety Analyses CI
15/09 CEL-SCI Corporation Presents Findings From Phase 3 Study Of Multikine At 6th World Congress On Otology, Rhinology And Laryngology CI
15/08 CEL-SCI Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
04/08 CEL-SCI Corporation Publishes Study Supporting Multikine Biomarker Strategy And Reports Survival Benefit In Oral Cancer CI
31/07 Certain Common Stock of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
31/07 Certain Warrants of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
31/07 Certain Stock Options of CEL-SCI Corporation are subject to a Lock-Up Agreement Ending on 31-JUL-2026. CI
30/07 CEL-SCI Corporation Announces Oncology Journal Accepts for Publication New Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients CI
13/07 CEL-SCI Corporation Launches FDA Registration-Enabling Phase 3 Confirmatory Study of Multikine for Newly Diagnosed Head and Neck Cancer CI
13/07 CEL-SCI to Launch Confirmatory Study of Multikine MT
24/06 Cel-Sci Corporation and Saudi Amarox Sign Agreement for Multikine Commercialization in Saudi Arabia CI
17/06 CEL-SCI Closes $2.5 Million Stock Offering MT
16/06 CEL-SCI Corporation and Amarox Enter Distribution and Commercialization Agreement for Multikine in Saudi Arabia CI
1 day+5.84%
1 week+5.07%
Current month+5.07%
1 month-47.08%
3 months-9.94%
Current year-72.43%
1 week 1.24
Extreme 1.24
1.46
1 month 1.24
Extreme 1.24
2.25
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
7.8
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
375.94
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Chairman 73 19/05/2025
Chairman 69 -
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Chief Executive Officer

2,621 0.0149%
30/09/26 Free

Chief Financial Officer

2,082 0.0118%
30/09/26 Free

Chief Technology Officer

1,165 0.0066%
Change 5-day change 1-year change 3-year change Capi.($)
+5.84%+5.07%-78.16%-97.93% 2.55Cr
-4.83%+3.51%+53.62%+61.75% 6.59TCr
-1.34%+2.98%+24.79%+100.18% 5.65TCr
+0.02%+1.07%+10.63%+76.66% 5.69TCr
+5.09%+9.89%+22.45%+107.48% 4.65TCr
+2.62%+1.68%+28.91%+37.01% 4.48TCr
+8.24%+0.51%+213.26%+792.66% 4.16TCr
-1.86%+10.13%+26.82%+53.22% 3.53TCr
-2.97%-9.84%+88.86%+76.17% 3.33TCr
-2.18%+7.06%+36.06%-4.95% 2.49TCr
Average +0.86%+3.43%+42.72%+120.23% 4.06TCr
Weighted average by Cap. +0.21%+3.40%+53.11%+142.94%

Financials

2026 *2027 *
Net sales - 59.72L 53.56L 48.95L 44.69L 84.19L 56Cr 86.84L 5.9Cr 2.35Cr 30Cr 2.24Cr 2.19Cr 95Cr
Net income -2.51Cr -2.25Cr -2.06Cr -1.88Cr -3.54Cr -235.8Cr -3.65Cr -25Cr -9.88Cr -125.82Cr -9.42Cr -9.21Cr -397.19Cr -2.95Cr -2.65Cr -2.42Cr -2.21Cr -4.16Cr -277.44Cr -4.29Cr -29Cr -12Cr -148.04Cr -11Cr -11Cr -467.33Cr
Net Debt -55.54L -49.81L -45.53L -41.56L -78.3L -52Cr -80.77L -5.49Cr -2.19Cr -28Cr -2.08Cr -2.04Cr -88Cr -53.39L -47.89L -43.76L -39.95L -75.27L -50Cr -77.64L -5.28Cr -2.1Cr -27Cr -2Cr -1.96Cr -85Cr
Projected Income Statement - Annual - CEL-SCI Corporation
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
06/26/06 $1.450 +5.84% 46,675
05/26/05 $1.370 -0.72% 99,185
04/26/04 $1.380 -2.13% 27,886
03/26/03 $1.410 +7.63% 2,15,690
02/26/02 $1.310 -5.07% 91,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - CEL-SCI Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.450USD
Average target price
12.50USD
Spread / Average Target
+762.07%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - CEL-SCI Corporation